Bill Yelle has 25 years of experience in the life sciences industry, including positions in corporate and business development, strategic planning, portfolio management, commercial operations and R&D.
Bill was previously Senior Vice President of Corporate Development and Licensing for Sunovion Pharmaceuticals Inc (formerly Sepracor Inc). In this role, he was responsible for overseeing all business development initiatives, as well as the alliance management function. Bill joined Sepracor in 1995 and was instrumental in the company’s transition from an early clinical stage organization into a fully-integrated pharmaceutical company, with involvement in key strategic and product development activities. This included the sale of Sepracor to Dainippon Sumitomo Pharma for $2.6 billion in 2009.
Prior to joining Sepracor in 1995, Bill held positions of increasing responsibility in Pfizer’s U.S. Pharmaceuticals group, including business development, new product planning, and organized customer marketing. He formerly worked in immunodiagnostic assay development at PB Diagnostics.
Bill received an MBA from Columbia University's Graduate School of Business Administration, a Masters of Science in Organic Chemistry from the University of California at Berkeley and a B.S. in Chemistry from the University of Massachusetts at Lowell.